ADMA Biologics Inc (NASDAQ:ADMA)’s stock price traded down 6.5% on Thursday . The company traded as low as $4.02 and last traded at $4.05, 834,200 shares were traded during mid-day trading. A decline of 5% from the average session volume of 881,807 shares. The stock had previously closed at $4.33.

A number of equities analysts recently weighed in on the stock. BidaskClub upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Dawson James downgraded ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 target price for the company. in a report on Monday, August 12th. Maxim Group set a $12.00 target price on ADMA Biologics and gave the company a “buy” rating in a report on Monday, October 21st. Finally, ValuEngine raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $10.20.

The company has a quick ratio of 3.76, a current ratio of 6.42 and a debt-to-equity ratio of 2.33. The business has a fifty day simple moving average of $4.49 and a 200 day simple moving average of $4.25. The company has a market cap of $260.40 million, a price-to-earnings ratio of -2.79 and a beta of 2.70.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. ADMA Biologics had a negative return on equity of 203.21% and a negative net margin of 260.92%. The company had revenue of $7.22 million during the quarter, compared to the consensus estimate of $5.71 million. Equities analysts anticipate that ADMA Biologics Inc will post -0.92 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in ADMA. Private Advisors LLC acquired a new stake in ADMA Biologics in the second quarter valued at $41,000. Parametric Portfolio Associates LLC acquired a new stake in ADMA Biologics in the second quarter valued at $49,000. Tower Research Capital LLC TRC lifted its holdings in ADMA Biologics by 13,268.0% in the second quarter. Tower Research Capital LLC TRC now owns 13,368 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 13,268 shares during the period. Citadel Advisors LLC lifted its holdings in ADMA Biologics by 96.3% in the second quarter. Citadel Advisors LLC now owns 22,187 shares of the biotechnology company’s stock valued at $86,000 after acquiring an additional 10,887 shares during the period. Finally, Rhumbline Advisers lifted its holdings in ADMA Biologics by 55.9% in the third quarter. Rhumbline Advisers now owns 45,841 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 16,443 shares during the period. 59.09% of the stock is owned by institutional investors.

ADMA Biologics Company Profile (NASDAQ:ADMA)

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

See Also: The basics of gap trading strategies

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.